Yso 4
Alternative Names: Yso-4; Yso4 programmeLatest Information Update: 28 May 2024
At a glance
- Originator YSOPIA Bioscience
- Class Bacteria; Mood stabilisers
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mood disorders
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in Mood disorders in France
- 29 Sep 2020 LNC Therapeutics is now called Ysopia Bioscience (Ysopia Bioscience pipeline, September 2020)
- 15 Apr 2020 Ysopia Bioscience entered an agreement with Spanish National Research Council (CSIC) for the treatment of mood disorder (Ysopia Bioscience pipeline, January 2021)